Human papillomaviruses have been implicated in many cutaneous diseases. Practicing dermatopathologists often consider using immunohistochemistry and in situ hybridization to help clarify the histologic diagnosis, particularly in cases with borderline or nondiagnostic features. We reviewed the current evidence behind the use of these two techniques in dermatopathology.
Human papillomaviruses have been implicated in many cutaneous diseases. Practicing dermatopathologists often consider using immunohistochemistry and in situ hybridization to help clarify the histologic diagnosis, particularly in cases with borderline or nondiagnostic features. We reviewed the current evidence behind the use of these two techniques in dermatopathology.
We identified only two studies utilizing the currently available immunohistochemical antibodies. We found more evidence regarding the use of in situ hybridization; however, the majority of this evidence focuses on diagnosing condylomas and other lesions of the genital skin. We also assessed current utilization patterns of attendees of the American Society of Dermatopathology annual meeting (Chicago, 2016) which revealed a wide spectrum of current utilization ranging from no use to regular use more than once per month. Two-thirds of respondents utilized these tests primarily when requested by the submitting clinician and one-third of the respondents utilize these tests reflexively in specific clinical scenarios. The AUC Task Force chose to evaluate the use of HPV ISH and IHC in dermatopathology. We chose these tests because they are often used by dermatopathologists and also requested by our clinical colleagues. In addition, we felt that there was a broad spectrum of current utilization of these tests ranging from dermatopathologists who never or rarely perform these studies to labs that routinely order them in specific situations.
HPV are double-stranded, nonenveloped deoxyribonucleic acid (DNA) viruses of the papovirus family. Over 100 subtypes have been described to date. These viruses have been implicated in many cutaneous diseases including: verruca, condyloma, verrucous carcinoma, squamous cell carcinoma (SCC) and squamous cell carcinoma in situ (SCCIS) of the nail unit, SCC/SCCIS of the genital skin and SCC/SCCIS in immunocompromised patients.
With respect to HPV ISH, many commercially available typespecific probes and "cocktails" are available; however, type-specific probes for HPV 6, 11, 16, 18, 31 and HPV 6, 11, 16, 18, 31, 33, 42 , 51, 52, 56 and 58 (Figure 1 ). Type-specific HPV antibodies are not widely commercially available at this time.
A literature review to identify the current scientific evidence behind the use of HPV ISH and IHC in dermatopathology was performed. Next, the scientific evidence was enumerated, evaluated and summarized. Finally, we utilized an audience response system during Short Course I "Best Practices" at the 51st annual meeting of the ASDP in Chicago, Illinois, to assess the current utilization patterns of attendees.
| MATERIAL AND METHODS

| Literature review
We developed a search strategy to identify relevant articles discussing the use of HPV IHC and ISH in various clinical scenarios encountered by dermatopathologists (Table 1) . A search for journal articles written in English was performed in PubMed. We excluded case series containing fewer than 3 cases, individual case reports and articles which solely used other forms of HPV detection or subtyping (such as PCR-based assays). With respect to HPV IHC, the search was limited to 1985 for the date of article submission since we were unable to identify any studies utilizing IHC prior to 1985. Of importance to note is that all of the studies performed prior to 2013 utilize an older "pan-HPV" antibody. It is unclear which specific HPV subtypes are targeted by this antibody and this antibody has also been reported to have a lower sensitivity than the current commercially available antibodies. 1 With respect to ISH, the search was limited to 1990 for the date of article submission. Prior to 1990, the currently available commercial type-specific probes were not accessible and researchers were creating individual probes which varied in sensitivity and specificity.
| Survey of current utilization
During the 51st annual meeting of the ASDP in Chicago, Illinois, an audience response system surveyed attendees of Short Course I "Best Practices" regarding their current utilization of HPV ISH and IHC. The audience was polled prior to the presentation of the literature overview using a web-based platform that allowed anyone in the audience with a smart phone, tablet or any other internet-connected device to participate in the poll.
| COMMENTS AND CONCLUSIONS
3.1 | Human papillomavirus 3.1.1 | HPV in situ hybridization in cutaneous lesions (Table 2) We identified 33 relevant articles and have summarized the studies according to HPV subtypes assessed and clinical scenario in Table 2 .
The majority of these articles assess condylomas or lesions histologically concerning for condylomas in the adult population.
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The sensitivities reported in these studies range from 53% to 100%
with the majority of studies finding sensitivities greater than 75%.
HPV 6 and 11 were the most common subtypes identified. Several studies compared histologically definitive condylomas with lesions "suggestive of" condyloma and lesions lacking any histologic features of condylomas. 2, 3, 6, 8, 17, 19, 20 These studies consistently found the highest rates of positivity in histologically definitive condylomas with lower rates for lesions "suggestive of" condyloma and the lowest rates of positivity in lesions lacking the histologic features of condyloma. We identified 5 articles assessing HPV ISH in condylomas in the pediatric population. 2, 17, [22] [23] [24] The sensitivities in the pediatric population ranged from 60% to 100% with only 1 study finding less than 80% positivity. HPV 6 and 11 were again the most common subtypes; however, multiple studies noted a significant percentage of cases with HPV 2 positivity, including 1 study which found this to be the most common subtype in the pediatric population. 22 Although we were unable to identify any articles specifically assessing lesions histologically consistent with seborrheic keratoses on the genital skin, lower abdomen or inner thighs in patients under 25, we did identify several studies which evaluated ISH in genital lesions "lacking the histologic features of condyloma." 3, 8, 19, 20 These studies showed very low sensitivities ranging from 3% to 21% with the majority showing sensitivities less than or equal to 10%. Interestingly, we identified 1 article assessing the frequency of HPV positivity by ISH in nongenital seborrheic keratoses. 25 The authors found 29% positivity with HPV 6 and 18 being the most common subtypes encountered.
We identified 5 articles assessing HPV ISH positivity in genital SCC/SCCIS. 8, 18, [26] [27] [28] The sensitivities in these studies ranged from There were 4 articles evaluating HPV positivity by ISH in verrucous carcinomas. 5, 9, 29, 30 The majority of the articles did not find any positivity (30 total cases). 9, 29, 30 One study revealed 5/6 cases positive. 5 HPV 6 and 11 were the most common subtypes.
The data regarding the use of HPV ISH for SCCIS/SCC of the nail unit or SCCIS/SCC in immunocompromised patients is very limited. We identified one small case series reviewing SCCIS/SCC of the nail unit. 31 The authors found 2/3 cases positive for HPV subtypes 16 and 18.
There is one study comparing HPV positivity in SCC between immunocompromised (organ transplant recipients) and immunocompetent patients. 32 The 34 The patients included in this study were immunocompetent and they identified HPV 2 in 3/5 cases. (Table 3) We identified 7 relevant articles assessing HPV detection by IHC in cutaneous lesions. 1, [35] [36] [37] [38] [39] [40] As mentioned previously, the majority of these articles used pan-HPV antibodies. 
| HPV immunohistochemistry in cutaneous lesions
| Current utilization of HPV ISH and IHC (Table 4)
We used an audience response system at the 53rd annual meeting of the ASDP (Chicago, 2016) to identify the current HPV ISH and IHC utilization patterns among attendees of Short Course I "Best Practices." We had between 133 and 138 respondents to each question related to HPV testing. We obtained some basic demographic information on this group which revealed that the majority of respondents are in an academic practice setting (47%). We had a relatively even distribution of experience in dermatopathology with 36% in training, 23% practicing less than 5 years, 22% practicing 5-10 years and 19% practicing more than 15 years. The majority of respondents were from the United States (93%) with the highest representation from the Central region (36%).
Fifty-seven percent of respondents are using HPV ISH or IHC once per month or less with the majority ordering the tests primarily when requested by the submitting clinician. However, 18% of respondents utilize this test more than once monthly, and the majority of these respondents are ordering the tests without additional input from the submitting clinician. Sixty-seven percent of respondents are using HPV IHC with approximately half performing this test within their institution. Sixty-four percent of respondents utilize HPV ISH with the majority sending the specimen to an outside institution to have the test performed.
| HPV IHC and ISH in cutaneous lesions-Summary
The majority of respondents surveyed at the 51st annual ASDP meeting are utilizing HPV ISH and IHC in their current practice. We Of note, this survey was presented prior to the review of the literature and reflects a baseline pattern of utilization that may not be based on the currently available scientific evidence. In addition, the majority of the respondents in this survey practiced in an academic setting.
Although there is a significant body of evidence using PCR-based assays to identify HPV in clinical scenarios encountered by dermatopathologists, a literature review revealed less evidence regarding the use of ISH and IHC in these settings. With respect to IHC, we identi- 
